Catalyst pharmaceuticals

Dedicated to Making a Meaningful Difference in the Lives of Patients Suffering from Rare and Difficult to Treat Diseases

NASDAQ: CPRX

November 2023

Forbes 2023 AMERICA'S BEST SMALL COMPANIES

BIOFLORIDA 2022 Company of the Year

Safe Harbor

This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All statements regarding our strategy, future operations, financial position, estimated revenues or losses, projected costs, prospects, plans, and objectives, other than statements of historical fact included in our filings with the U.S. Securities and Exchange Commission ("SEC"), are forward-looking statements. The language reflected in these statements only speaks as of the date that appears on the front cover of the presentation; the words "may," "will," "could," "would," "expect," "intend," "plan," "anticipate," "believe," "estimate," "project," "potential," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You should not place undue reliance on forward-looking statements. While we believe that we have a reasonable basis for each forward-looking statement that we make, we caution you that these statements are based on a combination of facts and factors currently known by us and projections of future events or conditions, about which we cannot be certain. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect our business, particularly those mentioned in the "Risk Factors" section of our Annual Report on Form 10-K filed with the SEC, reporting our financial position and results of operations as of and for the year ended December 31, 2022, as well as our subsequent reports filed with the SEC. In addition, market and industry statistics contained in this presentation are based on information available to us that we believe is accurate. This information is generally based on publications that are not produced for purposes of securities offerings or economic analysis. All forward-looking statements speak only as of the date that appears on the front cover of the presentation or the date of this presentation. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Catalyst Pharmaceuticals

An Emerging Leader in Rare Diseases

Execution Excellence

Proven track record in development and commercialization

Patient Focus

Dedicated to making a meaningful difference in the lives of patients suffering from rare diseases

Positioned For Growth

Focused on optimizing the product portfolio and investing in portfolio expansion opportunities

Growing Revenue With A Diversified Portfolio

Focus on Rare Neurological and Epileptic Disorders

Proprietary Portfolio of Products

Proven U.S. Commercial Capabilities

Neuromuscular Franchise

- FIRDAPSE® - rare neuromuscular disease
- AGAMREE® - rare muscular dystrophy disease

Epilepsy Franchise

- FYCOMPA® - epileptic seizures

Product Franchises

Neuromuscular	Epilepsy
FIRDAPSE® (amifampridine) Tablets 10 mg aGamree® (vamorolone) oral suspension 40mg/mL	Fycompa™ (perampanel) tablets CIII 2mg · 4mg · 6mg · 8mg · 10mg · 12mg

FIRDAPSE® – Proprietary Flagship Product

Only U.S. Approved Treatment for Lambert Eaton Myasthenic Syndrome (LEMS)

FIRDAPSE® (amifampridine) Tablets 10mg

Orally Delivered Potassium Channel Blocker

Clinically Proven To Maintain Muscle Strength And Mobility
Most Patients Respond And Remain On Treatment

- Flagship product approved in the U.S. in Nov 2018
- Product launched - Q1 2019
- Expanded indication in people ≥6 years of age
- Orphan Drug Exclusivity through 2025
- IP protection to 2037
- Strong intellectual property estate enhances durability
- A total of 8 patents: 6 listed in the Orange Book and 2 pending

Catalyst pharmaceuticals

Lambert Eaton Myasthenic Syndrome (LEMS)

A Rare Neuromuscular Autoimmune Disease

Affects Nerve-Muscle Communication



Most affected

Sometimes affected

Least affected

May cause:

- Weakening of upper arms and shoulders muscles
- Severe, debilitating, and progressive weakness in the upper legs and hips

Life-threatening weakness in respiratory muscles

Causing debilitating, progressive muscle weakness and fatigue

Onset in LEMS patients - 50 to 60 years of age

50% of people with LEMS have underlying cancer

Observed in ~3% of small cell lung cancer patients

Affects both women and men

FIRDAPSE - U.S. LEMS Market Opportunity

Significant Unmet Need

Affects ~3,600 - 5,600 people (U.S.)[1]

>**1100** LEMS-diagnosed patients ever **treated** with FIRDAPSE [2]

~**800** LEMS patients **diagnosed but not yet treated** with FIRDAPSE

> **2,900 LEMS undiagnosed** patients

Multiple Growth Drivers

Expanded educational programs to SCLC LEMS HCP's

100mg label expansion – PDUFA June 4, 2024

Seek to expand global footprint

Making A Meaningful Difference In Patients' Lives

[1] *Lambert Eaton Myasthenic Syndrome is Underrecognized in Small Cell Lung Cancer: An Analysis of Real-World Data*; presented IASLC 2023 World Conference on Lung Cancer; authors: David Morrell, Benjamin Drapkin, Guy Shechter, Regina Grebla;[2] Includes 225 patients now deceased

Catalyst pharmaceuticals

Small Cell Lung Cancer Tumor LEMS

Represents a Significant Growth Opportunity

Patient prevalence lung cancer

Small Cell Lung Cancer (SCLC)
(10% - 15% of Lung Cancer – midpoint 12.5%)

Lambert Eaton Myasthenic Syndrome SCLC patients
(~3% of SCLC)



- Many SCLC LEMS patients are undiagnosed with LEMS and are being treated by oncologists
- Oncologists typically refer SCLC patients diagnosed with LEMS to neurologists or neuromuscular specialists
- **~ 1,000 new potential** SCLC LEMS patients each year (*includes diagnosed and undiagnosed*)

Catalyst pharmaceuticals

FIRDAPSE: Expanding the Global Reach

Global Expansion Initiatives Underway

Japan

Currently, no approved therapy for LEMS

LEMS prevalence: ~1,200 people

DyDo Pharma* to develop & market the product

Anticipate NDA submission in Japan by YE 2023

Expect 10-year market exclusivity upon approval

Canada

Approved by Health Canada in August 2020

Canada LEMS Prevalence: ~ 300 people

KYE Pharmaceuticals has the exclusive license to market FIRDAPSE

Innovative drug data exclusivity to 2028

No drug application referencing data accepted before 2026

*DyDo, our partner in Japan, will submit their NDA for FIRDAPSE (amifampridine) to the Pharmaceuticals and Medical Devices Agency ("PMDA"). Upon acceptance of the submission of the NDA for FIRDAPSE in Japan, our territorial rights to develop and market FIRDAPSE under the license agreement with SERB will expand to include key markets in Asia, as well as in Central and South America.

aGamree®
(vamorolone) oral suspension 40mg/mL

FDA Approved:
Oct 26, 2023

Launch
Q1 2024

Designations:
Orphan Drug
Rare Pediatric Disease

AGAMREE® - Novel Corticosteroid

Treatment for Duchenne Muscular Dystrophy (DMD)



Potential To Deliver Meaningful Near & Long-term Value, Adding To Continued Growth Momentum

Approved for treatment in DMD patients ≥ 2yrs

May increase ambulation duration & mobility, improving QoL

Neuromuscular franchise team to launch product in Q1 2024

Optimize existing capabilities with minimal expansion

Comprehensive Patient Assistance Program upon launch

Orphan drug designation offers 7 years of market exclusivity

Pending patents out to 2040

Acquired North America License from Santhera Pharmaceuticals, July 2023. North American territories consist of the U.S., Canada, and Mexico

AGAMREE – Addresses Need for Tolerable Steroid

Steroids are the Backbone of DMD Therapy

AGAMREE - Compelling Safety Profile

In clinical studies, demonstrated:

- Proven efficacy, tolerability, safety, and ease of use
- Equivalent efficacy to prednisone
- Potential of significant reduction of steroid-associated side effect burden when compared with another corticosteroid, with benefits for
  - bone health
  - growth
  - behavior

U.S. DMD patient prevalence: ~ 11,000 to 13,000

DMD diagnosis rate; typically occurs at ages 2 - 5 years

DMD patients treated with corticosteroids at some point

Currently treated DMD patients receive concomitant steroid treatment



[1]Guglieri M et al (2022). JAMA Neurol. 2022;79(10):1005-1014.doi:10.1001/jamaneurol.2022.2480; Mah JK et al (2022). JAMA Netw Open.2022;5(1):e2144178.doi:10.1001/jamanetworkopen.2021.44178.; Guglieri M et al (2022) JAMA. doi:10.1001/jama.2022.4315;Heier CR et al (2019). Life Science Alliance DOI: 10.26508; Liu X et al (2020). Proc Natl Acad Sci USA 117:24285-24293

Catalyst pharmaceuticals

FYCOMPA® (perampanel) CIII

Established, First-In-Class Commercial Epilepsy Asset

- Synergistic neurology expansion
- Acquired U.S. rights in Jan 2023
- Franchise teams fully engaged - May 2023
- Franchise physician call points overlap - 45%
- Compelling product net revenue contribution
- Seek to expand into rare epilepsy or neuroscience adjacencies

FYCOMPA® is approved to treat:



*Taken with another antiseizure medication or alone for patients 4 years of age and older.

†Taken with another antiseizure medication for patients 12 years of age and older.

Catalyst pharmaceuticals

FYCOMPA® – Epilepsy Franchise

Only Non-competitive AMPA Receptor Antagonist

- Patent exclusivity until at least May 2025
- Broad-spectrum efficacy
- Well-tolerated, minimal drug-to-drug interactions, and no contraindications
- Simple once-a-day dosing
- Long half-life, relieving the anxiety of breakthrough seizures if a dose is missed
- >70% retention rate for adult patients
- Seizure-freedom rate is ˜ 72% when used adjunctively

FYCOMPA has been designated in the U.S. as a federally-controlled substance (CIII). For Full Prescribing Information, including Boxed WARNING for FYCOMPA®, please visit **www.fycompa.com**.

Catalyst pharmaceuticals

FYCOMPA – Significant Market Opportunity

Epilepsy - High Unmet Medical Need

Epilepsy is 4th most common neurological disorder after Alzheimer's disease, migraine, and stroke[1]

- ~3.5M patients in the U.S. with active epilepsy and ~500K children[2]
- ~150,000 new patients per year in U.S.[3]
- ~30 - 40% of all people with epilepsy still fail to respond to treatment despite the availability of a wide variety of anti-seizure medications

Evolving into a precision medicine composed of a variety of well-defined rare epilepsies of genetic origin

Fycompa™

[1]England MJ, Liverman CT, Schultz AM, Strawbridge LM, eds. Epilepsy Across the Spectrum: Promoting Health and Understanding. Washington, DC: National Academies Press (US); 2012. [2]CDC Epilepsy Data and Statistics; Epilepsy Prevalence in the US; [3]Examining the Economic Impact and Implications of Epilepsy, AJMC (US); 2020

Catalyst pharmaceuticals

Expanded Product Portfolio Growth

Sustained Commercial Execution

3Q 2022 vs 3Q 23 Net Revenue Performance





Forecast 2023 Total Net Revenues of between $390M - $395M

Catalyst pharmaceuticals

Catalyst Pharmaceuticals Pipeline



[1]EAP=Expanded Access Program; ISI investigator Sponsored IND

[2]Orphan Drug Designation

[3]Breakthrough Therapy Designation

[4]Lead Indication

*FIRDAPSE is currently approved in the U.S. for the treatment of LEMS in patients 6 years of age and older

Strategic Growth Initiatives
Building on the Momentum

Expand Commercial Footprint	Explore commercial add-on assets both in the US & Globally Synergistic expertise to foster innovations Harness operational capabilities and industry expertise
Expand Portfolio in Rare & Orphan Diseases	Seek transformational partnerships to accelerate growth into new therapeutic areas and larger markets Focused on rare neurological and epileptic disease opportunities
Invest in Portfolio Diversification	Strong balance sheet reinforces delivering attractive opportunities Well-positioned to achieve long-term growth

Strong Foundation to Deliver Long-Term Growth

Achievements

- ✓ Completed the U.S. acquisition of FYCOMPA in Q1 2023
- ✓ Expanded focus on small-cell lung cancer patients comorbid with LEMS in Q1 23
- ✓ Completed the seamless U.S. FYCOMPA commercial and MSL team integration in Q2 2023
- ✓ Launched Environmental, Social, and Governance “ESG” inaugural report in Q2 2023
- ✓ Completed the acquisition of the North American License for AGAMREE (vamorolone) in Q3 2023
- ✓ Acceptance of FIRDAPSE sNDA seeking an increased maximum daily dose of 100mg in Q4 23
- ✓ Approval for AGAMREE in Q4 2023
- ✓ Received two new patent allowances for FIRDAPSE in Q4 2023

Upcoming Milestones

- Expect FIRDAPSE (amifampridine) NDA filing in Japan by YE 2023
- Anticipate AGAMREE commercial launch in Q1 2024
- FIRDAPSE sNDA PDUFA date is on June 4, 2023

Q3 2023 Financial Highlights

FY 2023 Total Revenue of Between $390M - $395M

For the Three Months Ended September 30th	2023	2022	% Change
Total Net Product Revenues	$102,617	$57,173	79.5%
FIRDAPSE Net Product Revenues	$66,224	$57,173	15.8%
FYCOMPA Net Product Revenues	$36,393	N/A	N/A
GAAP Net Income (Loss)	$(30,764)	$22,748	(235.2)%
Non-GAAP Net Income **	$55,870	$28,615	95.2 %
GAAP Net Income (Loss) Per Share – Diluted	$(0.29)	$0.20	(242.1)%
Non-GAAP Net Income Per Share – Diluted**	$ 0.49	$0.26	88.5 %

*Non-GAAP financial measures are provided as additional information and not as an alternative to Catalyst's financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP). These non-GAAP financial measures are intended to enhance an overall understanding of Catalyst's current financial performance.

Strong Financial Position
Underscores Successful Execution

(In Millions)

Q3 23 Results	
Cash Position as of Sept 30, 2023	$121.0
Total Revenues	$102.7
YoY Net Revenue Increase	79.4%
Net Product Revenue Growth Increase	
FIRDAPSE YTD	23.1%
FYCOMPA compared to Q2 '23	5.2%
FY 2023 Forecast	
Total Revenue Guidance	$390 - $395



NASDAQ: CPRX

2002 Founded	2006 IPO	Market Cap ~$1.34B*

*Market Cap as of Nov 8, 2023

NASDAQ: CPRX